These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

247 related articles for article (PubMed ID: 33888588)

  • 1. The loops of the N-SH2 binding cleft do not serve as allosteric switch in SHP2 activation.
    Anselmi M; Hub JS
    Proc Natl Acad Sci U S A; 2021 Apr; 118(17):. PubMed ID: 33888588
    [TBL] [Abstract][Full Text] [Related]  

  • 2. An allosteric interaction controls the activation mechanism of SHP2 tyrosine phosphatase.
    Anselmi M; Hub JS
    Sci Rep; 2020 Oct; 10(1):18530. PubMed ID: 33116231
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Structural Determinants of Phosphopeptide Binding to the N-Terminal Src Homology 2 Domain of the SHP2 Phosphatase.
    Anselmi M; Calligari P; Hub JS; Tartaglia M; Bocchinfuso G; Stella L
    J Chem Inf Model; 2020 Jun; 60(6):3157-3171. PubMed ID: 32395997
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Structural mechanism associated with domain opening in gain-of-function mutations in SHP2 phosphatase.
    Darian E; Guvench O; Yu B; Qu CK; MacKerell AD
    Proteins; 2011 May; 79(5):1573-88. PubMed ID: 21365683
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Discriminating between competing models for the allosteric regulation of oncogenic phosphatase SHP2 by characterizing its active state.
    Calligari P; Santucci V; Stella L; Bocchinfuso G
    Comput Struct Biotechnol J; 2021; 19():6125-6139. PubMed ID: 34900129
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Counteracting effects operating on Src homology 2 domain-containing protein-tyrosine phosphatase 2 (SHP2) function drive selection of the recurrent Y62D and Y63C substitutions in Noonan syndrome.
    Martinelli S; Nardozza AP; Delle Vigne S; Sabetta G; Torreri P; Bocchinfuso G; Flex E; Venanzi S; Palleschi A; Gelb BD; Cesareni G; Stella L; Castagnoli L; Tartaglia M
    J Biol Chem; 2012 Aug; 287(32):27066-77. PubMed ID: 22711529
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phosphotyrosine couples peptide binding and SHP2 activation via a dynamic allosteric network.
    Marasco M; Kirkpatrick J; Nanna V; Sikorska J; Carlomagno T
    Comput Struct Biotechnol J; 2021; 19():2398-2415. PubMed ID: 34025932
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Exploring the Allosteric Mechanism of Src Homology-2 Domain-Containing Protein Tyrosine Phosphatase 2 (SHP2) by Molecular Dynamics Simulations.
    Wang Q; Zhao WC; Fu XQ; Zheng QC
    Front Chem; 2020; 8():597495. PubMed ID: 33330386
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Study on the allosteric activation mechanism of SHP2
    Liu L; Cheng Y; Zhang Z; Li J; Geng Y; Li Q; Luo D; Liang L; Liu W; Hu J; Ouyang W
    Phys Chem Chem Phys; 2023 Sep; 25(35):23588-23601. PubMed ID: 37621251
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phosphopeptide binding to the N-SH2 domain of tyrosine phosphatase SHP2 correlates with the unzipping of its central β-sheet.
    Marasco M; Kirkpatrick J; Carlomagno T; Hub JS; Anselmi M
    Comput Struct Biotechnol J; 2024 Dec; 23():1169-1180. PubMed ID: 38510972
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Intramolecular Interaction with the E6 Region Stabilizes the Closed Conformation of the N-SH2 Domain and Concurs with the Self-Inhibitory Docking in Downregulating the Activity of the SHP2 Tyrosine Phosphatase: A Molecular Dynamics Study.
    Bellacchio E
    Int J Mol Sci; 2022 Apr; 23(9):. PubMed ID: 35563185
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Exploring the Distinct Binding and Activation Mechanisms for Different CagA Oncoproteins and SHP2 by Molecular Dynamics Simulations.
    Wang Q; Zhao WC; Fu XQ; Zheng QC
    Molecules; 2021 Feb; 26(4):. PubMed ID: 33562680
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Molecular basis of gain-of-function LEOPARD syndrome-associated SHP2 mutations.
    Yu ZH; Zhang RY; Walls CD; Chen L; Zhang S; Wu L; Liu S; Zhang ZY
    Biochemistry; 2014 Jul; 53(25):4136-51. PubMed ID: 24935154
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The pathogenic T42A mutation in SHP2 rewires the interaction specificity of its N-terminal regulatory domain.
    van Vlimmeren AE; Voleti R; Chartier CA; Jiang Z; Karandur D; Humphries PA; Lo WL; Shah NH
    Proc Natl Acad Sci U S A; 2024 Jul; 121(30):e2407159121. PubMed ID: 39012820
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Protein tyrosine phosphatase SHP2/PTPN11 mistargeting as a consequence of SH2-domain point mutations associated with Noonan Syndrome and leukemia.
    Müller PJ; Rigbolt KT; Paterok D; Piehler J; Vanselow J; Lasonder E; Andersen JS; Schaper F; Sobota RM
    J Proteomics; 2013 Jun; 84():132-47. PubMed ID: 23584145
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Monobody Inhibitor Selective to the Phosphatase Domain of SHP2 and its Use as a Probe for Quantifying SHP2 Allosteric Regulation.
    Sha F; Kurosawa K; Glasser E; Ketavarapu G; Albazzaz S; Koide A; Koide S
    J Mol Biol; 2023 Apr; 435(8):168010. PubMed ID: 36806475
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dissection of the BCR-ABL signaling network using highly specific monobody inhibitors to the SHP2 SH2 domains.
    Sha F; Gencer EB; Georgeon S; Koide A; Yasui N; Koide S; Hantschel O
    Proc Natl Acad Sci U S A; 2013 Sep; 110(37):14924-9. PubMed ID: 23980151
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Probing the acting mode and advantages of RMC-4550 as an Src-homology 2 domain-containing protein tyrosine phosphatase (SHP2) inhibitor at molecular level through molecular docking and molecular dynamics.
    Wang RR; Liu WS; Zhou L; Ma Y; Wang RL
    J Biomol Struct Dyn; 2020 Mar; 38(5):1525-1538. PubMed ID: 31043123
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Targeting SHP2 Cryptic Allosteric Sites for Effective Cancer Therapy.
    Rehman AU; Zhao C; Wu Y; Zhu Q; Luo R
    Int J Mol Sci; 2024 Jun; 25(11):. PubMed ID: 38892388
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Exploring the mechanism of the potent allosteric inhibitor compound2 on SHP2
    Zhou L; Feng Y; Ma YC; Zhang Z; Wu JW; Du S; Li WY; Lu XH; Ma Y; Wang RL
    J Mol Graph Model; 2021 Mar; 103():107807. PubMed ID: 33338846
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.